A patent protects a mechanism. It does not protect a share of the benefit. Those are different things, and the gap between them is where a great deal of intellectual property value quietly disappears.

Cardiology supplied the evidence this month. AstraZeneca and Ionis ran a 1,432-patient Phase 3 trial of a transthyretin silencer in ATTR-CM, a progressive heart muscle disease. The mechanism works. The trial failed. Around 57 per cent of patients were already taking an older oral stabiliser when they enrolled, and roughly a quarter more started one during the study. In those patients the silencer added nothing measurable. A pre-specified subgroup taking the silencer on its own did show a benefit, but the primary endpoint was gone, and a competitor left a contested billion-dollar market.

Nothing was wrong with the patents. The incumbent standard of care had already captured most of the benefit the new mechanism had to offer. A differentiated technology is an option, not a position, which is the same lesson I drew from India’s electrification build-out in Capacity Is Not a Moat.

What this means for your patent strategy

Three disciplines follow, and none of them are specific to pharmaceuticals.

– Value your rights against the market’s default, not against nothing. Your exclusivity is worth the increment you add to what the customer is already using. Where the incumbent captures that increment, the patent is still valid and the position is still empty.

– Treat combination and sequencing rights as assets in their own right. Claims to the combination, the regimen and the order of use, and the contractual right to generate data alongside the incumbent’s product, are secured years before the evidence exists. They are cheap then and unavailable later.

– Read your evidence plan as an IP decision. The comparator you choose decides which claims your data can support and which part of the market your patents can actually reach. In pharmaceuticals that is trial design. Elsewhere it is the benchmark, the reference architecture or the interoperability target.

There is a mirror image worth holding in view. Sanofi lost the mRNA product race and can still tax the winners, because it owns the delivery platform they all need, a posture I examined in Who Gets Paid for the Platform. One company owned a mechanism the market could route around. The other owns a position the market cannot.

Assets do not lose value on their own. The board they are played on moves, which was the argument in Your patents didn’t lose value. The board where you play them changed. So the question for your next portfolio review is not whether your patents cover your technology. It is whether they cover the position your technology will be judged from, against the incumbent your customers have already chosen.

Read the article: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs, Andrew Joseph, STAT, 28 August 2026.